This study evaluated the effect of DA-8159, a new phosphodiesterase 5 inhibitor, on the compensatory development of right ventricular hypertrophy in monocrotaline (MCT)-induced pulmonary hypertension (PH). Rats treated with subcutaneous MCT were divided into three groups, which received DA-8159 1 mg/kg, DA-8159 5 mg/kg or saline-vehicle orally, twice daily for 21 days. The vehicle group demonstrated increased right ventricular weight, pulmonary artery medial wall thickening, myocardial fibrosis, increased plasma cyclic guanosine monophosphate (cGMP) concentration and reduced body weight gains. DA-8159, however, markedly attenuated the compensatory development of right ventricular hypertrophy and pulmonary artery medial wall thickening, amplified the increase in plasma cGMP levels and increased lung cGMP concentrations. In addition, DA-8159 prevented myocardial fibrosis induced by MCT. These results demonstrate that DA-8159 attenuates the compensatory development of right ventricular hypertrophy in a rat model of PH. DA-8159 might, therefore, be a useful treatment option for PH, but its efficacy in humans needs evaluating.
RichSDantzkerDRAyresSMBergofskyEHBrundageBHDetreKM: Primary pulmonary hypertension. A national prospective study. Ann Intern Med1987; 107: 216–223.
2.
HanasatoNOkaMMuramatsuMNishinoMAdachiHFukuchiY: E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol1999; 277: 225–232.
3.
BarstRJRubinLJLongWAMcGoonMDRichSBadeschDB: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med1996; 334: 296–302.
Pepke-ZabaJHigenbottamTWDinh-XuanATStoneDWallworkJ: Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet1991; 338: 1173–1174.
6.
TroncyEFrancoeurMBlaiseG: Inhaled nitric oxide: clinical applications, indications, and toxicology. Can J Anaesth1997; 44: 973–988.
7.
ThomasMKFrancisSHCorbinJD: Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase. J Biol Chem1990; 265: 14964–14970.
8.
KodamaKAdachiH: Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J Pharmacol Exp Ther1999; 290: 748–752.
9.
SchermulyRTKrupnikETenorHSchudtCWeissmannNRoseF: Coaerosolization of phosphodiesterase inhibitors markedly enhances the pulmonary vasodilatory response to inhaled iloprost in experimental pulmonary hypertension. Maintenance of lung selectivity. Am J Respir Crit Care Med2001; 164: 1694–1700.
10.
SchermulyRTRoehlAWeissmannNGhofraniHALeuchteHGrimmingerF: Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol2001; 281: 1361–1368.
11.
WeimannJUllrichRHromiJFujinoYClarkMWBlochKD: Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology2000; 92: 1702–1712.
12.
WilkensHGuthAKonigJForestierNCremersBHennenB: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation2001; 104: 1218–1222.
ZieglerJWIvyDDWigginsJWKinsellaJPClarkeWRAbmanSH: Effects of dipyridamole and inhaled nitric oxide in pediatric patients with pulmonary hypertension. Am J Respir Crit Care Med1998; 158: 1388–1395.
15.
AbramsDSchulze-NeickIMageeAG: Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart2000; 84: E4.
16.
PrasadSWilkinsonJGatzoulisMA: Sildenafil in primary pulmonary hypertension. N Engl J Med2000; 343: 1342.
17.
OhTYKangKKAhnBOYooMKimWB: Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159. Arch Pharm Res2000; 23: 471–476.
18.
BangMYKangKKAhnBOShimHJKimSHYooM: Tolerance and pharmacokinetics of single-dose DA-8159, in healthy male. 10th ISSIR, Canada, Montreal, 2002; Abstract No. CP5.44.
19.
ChenLGanXTHaistJVFengQLuXChakrabartiSKarmazynM: Attenuation of compensatory right ventricular hypertrophy and heart failure following monocrotaline-induced pulmonary vascular injury by the Na+-H+ exchange inhibitor cariporide. J Pharmacol Exp Ther2001; 298: 469–476.
20.
DundoreRLClasDMWheelerLTHabeebPGBodeDCBuchholzRA: Zaprinast increases cyclic GMP levels in plasma and in aortic tissue of rats. Eur J Pharmacol1993; 249: 293–297.
21.
TakahashiTKandaTInoueMSuzukiTKobayashiIKodamaK: A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Life Sci1996; 59: 371–377.
22.
CassisLARippetoePESoltisEEPainterDJFitzRGillespieMN: Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP 753), a nonpeptide angiotensin type 1 receptor antagonist. J Pharmacol Exp Ther1992; 262: 1168–1172.
23.
SchultzeAERothRA: Chronic pulmonary hypertension — the monocrotaline model and involvement of the hemostatic system. J Toxicol Environ Health B Crit Rev1998; 1: 271–346.
24.
RosenbergHCRabinovitchM: Endothelial injury and vascular reactivity in monocrotaline pulmonary hypertension. Am J Physiol1998; 255: 1484–1491.
25.
NakazawaHHoriMOzakiHKarakiH: Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats. Br J Pharmacol1999; 128: 1098–1004.
26.
PichardoJPalaceVFarahmandFSingalPK: Myocardial oxidative stress changes during compensated right heart failure in rats. Mol Cell Biochem1999; 196: 51–57.
27.
DinermanJLLowensteinCJSnyderSH: Molecular mechanisms of nitric oxide regulation. Potential relevance to cardiovascular disease. Circ Res1993; 73: 217–222.
28.
PolsonJBStradaSJ: Cyclic nucleotide phosphodiesterases and vascular smooth muscle. Annu Rev Pharmacol Toxicol1996; 36: 403–427.
29.
YamaguchiKOkaMNishinoMHanasatoNKiraSFukuchiY: E4021, a cGMP phosphodiesterase inhibitor, is a selective pulmonary vasodilator in chronically hypoxic pulmonary hypertensive rats. Nihon Kokyuki Gakkai Zasshi1998; 36: 23–28.
30.
RosenkrantzJGLynchFPVogelJH: Hypoxic pulmonary hypertension: its modification by dipyridamole. J Surg Res1972; 12: 330–333.
31.
McMahonTJIgnarroLJKadowitzPJ: Influence of Zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J Appl Physiol1993; 74: 1704–1711.
32.
BranerDAFinemanJRChangRSoiferSJ: M&B 22948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol1993; 264: 252–258.
33.
CohenAHHansonKMorrisKFoutyBMcMurtyIFClarkeW: Inhibition of cyclic 3′–5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest1996; 97: 172–179.
34.
DukarmRCRussellJAMorinFC3rdPerryBJSteinhornRH: The cGMP-specific phosphodiesterase inhibitor E4021 dilates the pulmonary circulation. Am J Respir Crit Care Med1999; 160: 858–865.
